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A process for the preparation of Indoximod 
Field of the invention:  
 The present invention relates to a process for the preparation of 1-methyl-D-
tryptophan which is represented by the following structural formula-1. 
       
Formula-1    
                    
Background of the invention: 
 1-methyl-D-tryptophan is generally known as Indoximod. Indoximod is under 
clinical trials phase-II for the treatment of inhibition of indoleamine-2,3-dioxygenase 
pathway. 
 
 Heterocycles 1988, 27(12), 2795-2802 discloses the preparation of Indoximod 
by the methylation of D-tryptophan using methyl iodide in the presence of metallic 
sodium in liquor ammonia. 
 
 There is a still need to develop a process for the preparation of the compound 
of formula-1. 
 
Brief Description of the Drawings: 
Figure-1: Illustrates the PXRD pattern of Indoximod. 
 
Brief description of the invention: 
In an embodiment, the present invention provides a process for the preparation 
of Indoximod.  
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Detailed description of the invention: 
 As used herein the term “solvent” used in the present invention refers to 
“hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, pet ether, benzene, 
toluene, pentane, cycloheptane, methyl cyclohexane, ethylbenzene, m-, o-, or p-
xylene, or naphthalene and the like; “ether solvents” such as dimethoxymethane, 
tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol 
dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, 
diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl 
methyl ether,  1,2-dimethoxy ethane and the like; “ester solvents” such as methyl 
acetate, ethyl acetate, isopropyl acetate, n-butyl acetate and the like; “polar-aprotic 
solvents such as dimethylacetamide (DMA), dimethylformamide (DMF), 
dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and the like; “chloro 
solvents” such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride 
and the like; “ketone solvents” such as acetone, methyl ethyl ketone, methyl 
isobutylketone and the like; “nitrile solvents” such as acetonitrile, propionitrile, 
isobutyronitrile and the like; “alcohol solvents” such as methanol, ethanol, n-
propanol, isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-
fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene 
glycol), 2-methoxyethanol, l, 2-ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, 
neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monoethyl ether, 
cyclohexanol, benzyl alcohol, phenol, or glycerol and the like; “polar solvents” such 
as water or mixtures thereof. 
 
As used herein the present invention the term “base” refers to inorganic bases 
like “alkali metal carbonates” such as sodium carbonate, potassium carbonate, lithium 
carbonate and the like; “alkali metal bicarbonates” such as sodium bicarbonate, 
potassium bicarbonate and the like; “alkali metal hydroxides” such as sodium 
hydroxide, potassium hydroxide, lithium hydroxide and the like; alkali metal hydrides 
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such as sodium hydride, potassium hydride, lithium hydride and the like; alkali metal 
amides such as sodium amide, potassium amide, lithium amide and the like; ammonia 
such as liquor ammonia, ammonia gas, alcoholic ammonia and the like; and organic 
bases like dimethylamine, diethylamine, diisopropyl amine, diisopropylethylamine, 
diisobutylamine, triethylamine, tertiary butyl amine, benzyl amine, “alkali metal 
alkoxides” such as sodium methoxide, sodium ethoxide, potassium methoxide, 
potassium ethoxide, sodium tert.butoxide, potassium tert.butoxide, lithium 
tert.butoxide and the like; pyridine, 4-dimethylaminopyridine (DMAP), N-methyl 
morpholine (NMM), 2,6-lutidine, lithium diisopropylamide; organosilicon bases such 
as lithium hexamethyldisilazide (LiHMDS), sodium hexamethyldisilazide 
(NaHMDS), potassium hexamethyldisilazide (KHMDS) or mixtures thereof. 
 
In an embodiment, the present invention provides a process for preparation of 
Indoximod of formula-1 comprising: 
a) reacting D-tryptophan of formula-2 with di-tert-butyl dicarbonate [DiBOC] in a 
solvent optionally in the presence of base to provide (R)-2-((tert-
butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoic acid of formula-3, 
b) methylating (R)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoic acid 
of formula-3 with methylating agent in presence of a base in a solvent to provide 
(R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl)propanoic acid of 
formula-4, 
c) deprotecting the (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-
yl)propanoic acid with an acid in solvent to provide Indoximod of formula-1. 
Base in step-a) is defined as above. 
The methylating agent in step-b) is selected from dimethyl sulphate, trimethyl 
phosphate or methyl iodide; base in step-b) is defined as above.  
The acid in step-c) is selected from “inorganic acids” such as hydrochloric 
acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid; and “organic 
acids” such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, 
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caproic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, oxalic acid, malonic 
acid, maleic acid, fumaric acid, malic acid, succinic acid, citric acid, aspartic acid, 
tartaric acid, mandelic acid, benzoic acid, salicylic acid, substituted/unsubstituted 
alkyl/aryl sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, 
propanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 
naphthalenesulfonic acid and the like. 
The solvent in steps a) to c) is selected from alcohol solvents, chloro solvents, 
ether solvents, ester solvents, polar aprotic solvents, hydrocarbon solvents, ketone 
solvents, water and polar solvents or mixtures thereof. 
 
Another embodiment of the present invention provides the process for the 
preparation of substantially pure (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-
1H-indol-3-yl)propanoic acid having HPLC purity of greater than about 99% 
comprising: 
a) dissolving (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl) 
propanoic acid in a solvent, 
b) isolating substantially pure (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-
indol-3-yl)propanoic acid having HPLC purity of grater than about  99%. 
Dissolving (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl) 
propanoic acid in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; solvent is selected from suitable solvent is 
selected from alcohol solvents, chloro solvents, ketone solvents, ester solvents, ether 
solvents, polar solvents such as water and/or mixtures thereof; isolating substantially 
pure (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl)propanoic acid 
having the HPLC purity of greater than about 99% in step-b) is by solvent removal by 
known techniques which are selected from distillation, decanting, filtration, cooling 
the mixture to lower temperatures to precipitate the solid followed by filtration of the 
mixture, crystallization; or by combining with an anti-solvent. 
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The present invention is described in the following scheme: 
 
Indoximod obtained according to the present invention is characterized by its 
PXRD {Powder X-Ray Diffractogram} as illustrated in figure-1. 
 
Indoximod obtained according to the present invention is having a purity of 
>98%, preferably >99%, more preferably >99.5% by HPLC {High Performance 
Liquid Chromatography}. 
 
 Indoximod of formula-1 produced by the processes of the present invention 
can be further micronized or milled to get desired particle sizes to achieve desired 
solubility profile based on different forms of pharmaceutical composition 
requirements. Techniques that may be used for particle size reduction include but not 
limited to a single or multi-stage micronization using cutting mills, pin/cage mills, 
hammer mills, jet mills, fluidized bed jet mills, ball mills and roller mills. Milling or 
micronization may be performed before drying or after drying of the product. 
 
Indoximod obtained according to the present invention has particle size of less 
than about 300 μm or less than about 200 μm or less than about 150 μm or less than 
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about 100 μm or less than about 50 μm or any other suitable particle sizes. 
The best mode of carrying out the present invention was illustrated by the 
below mentioned examples. These examples are provided as illustration only and 
hence should not be construed as limitation of the scope of the invention. 
 
Examples: 
Example-1: Preparation of (R)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl) 
propanoic acid compound of formula-3 
DiBOC (128.2 g) was slowly added to the mixture of D-tryptophan (100 g), sodium 
hydroxide (49 g) and water (800 ml) at 25-30°C and stirred for 4 hours at the same 
temperature. Washed the reaction mixture with toluene and cooled the obtained 
mixture to 0-5°C. Ethyl acetate was added to the mixture at 0-5°C, acidified with 
aqueous hydrochloric acid and stirred for 20 minutes at the same temperature. 
Separated both organic and aqueous layers and the aqueous layer was extracted with 
ethyl acetate. Combined the organic layers and was washed with water and followed 
by with aqueous sodium chloride solution. Distilled off solvent completely from the 
organic layer and co-distilled with water. To this obtained compound water (800 ml) 
was added at 25-30°C and stirred for 2 hours at the same temperature. Filtered the 
solid, washed with water and dried to get the title compound.  
Yield: 136 g; purity by HPLC: 99.89%.  
 
Example-2: Preparation of (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-
indol-3-yl)propanoic acid compound of formula-4 
Sodium tertiary butoxide (40 g) was slowly added to a pre-cooled solution of (R)-2-
((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoic acid compound of formula-
3 (50 g) in dimethylformamide (200 ml) at 0-5°C and stirred the reaction mixture. To 
this reaction mixture methyl iodide (35 g) was slowly added at 0-5°C and stirred the 
reaction mixture. The reaction was quenched with water at 0-5°C, ethyl acetate was 
added. Acidified the reaction mixture using aqueous hydrochloric acid at 0-5°C and 
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stirred for 20 minutes at the same temperature. Separated both organic and aqueous 
layers and aqueous layer was extracted with ethyl acetate. Combined the organic 
layers and washed with water and followed by with aqueous sodium chloride 
solution. Distilled off solvent completely from organic layer and co-distilled with 
cyclohexane. Isopropanol (100 ml) and cyclohexane (150 ml) were added to the 
obtained compound at 25-30°C, heated to 55-60°C and stirred for 20 minutes at the 
same temperature. Cooled the mixture to 25-30°C and stirred for 30 minutes at the 
same temperature. Further cooled to 5-10°C and stirred for 2 hours at the same 
temperature. Filter the precipitated solid, washed with mixture of isopropanol and 
cyclohexane and dried to get the title compound. 
Yield: 32 g; purity by HPLC: 99.52%. M.R. {Melting Range}:150-152°C. 
 
Example-3: Preparation of Indoximod of formula-1 
A mixture of (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-
yl)propanoic acid (100 g), isopropanol (500 ml) and hydrochloric acid (100 ml) at 25-
30°C was heated to 60-65°C and stirred for 5 hours at the same temperature. Distilled 
off solvent completely from the reaction mixture to obtain residue. Obtained residue 
was cooled to 25-30°C, water and ethyl acetate were added. Separated both organic 
and aqueous layers and aqueous layer was washed with ethyl acetate. Aqueous layer 
was basified by using aqueous sodium hydroxide solution at 25-30°C and stirred for 
20 minutes at the same temperature. Ethyl acetate was added to the reaction mixture 
at 25-30°C and stirred for 20 minutes at the same temperature. Separated both organic 
and aqueous layers. Basic carbon was added to aqueous layer 25-30°C, filtered 
through hyflow bed and washed with water. pH of aqueous layer was adjusted to 6.0 
by using aqueous hydrochloric acid at 25-30°C and stirred for 2 hours at the same 
temperature. Filtered the precipitated solid and washed with water. Water (1000 ml) 
was added to the obtained compound at 25-30°C, heated to 80-85°C and stirred for 30 
minutes. Cooled the mixture to the 25-30°C and stirred for 2 hours at the same 
8
: A process for the preparation of Indoximod
Published by Technical Disclosure Commons, 2020
8 
temperature. Filtered the solid, washed with water and dried to get the title 
compound.  
Yield: 50 g; purity by HPLC: 99.91%. PXRD of the obtained compound is as 
illustrated in figure-1. 
 
Example-4: Preparation of Indoximod 
A mixture of (R)-2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-
yl)propanoic acid (150 g), isopropanol (750 ml) and hydrochloric acid (150 ml) at 25-
30°C was heated to 60-65°C and stirred for 5 hours at the same temperature. Distilled 
off solvent completely from the reaction mixture to obtain residue. Obtained residue 
was cooled to 25-30°C, water and ethyl acetate were added. Separated both organic 
and aqueous layers and aqueous layer was washed with ethyl acetate. Aqueous layer 
was basified by using aqueous sodium hydroxide solution at 25-30°C and stirred for 
at the same temperature. Ethyl acetate was added to the reaction mixture at 25-30°C 
and stirred for 20 minutes at the same temperature. Separated both organic and 
aqueous layers. Basic carbon treatment was given to aqueous layer, pH of aqueous 
layer was adjusted to 6.0 by using aqueous hydrochloric acid at 25-30°C and stirred 
for 2 hours at the same temperature. Filtered the precipitated solid and washed with 
water. Water (1500 ml) was added to the obtained compound at 25-30°C, heated to 
80-85°C and stirred for 30 minutes. Cooled the mixture to the 25-30°C and stirred for 
2 hours at the same temperature. Filtered the solid and washed with water. Isopropyl 
alcohol (1200 ml) was added to obtained compound at 25-30°C and stirred at the 
same temperature. Filter the solid, washed with isopropyl alcohol and dried to get the 
title compound.  
Yield: 72 g; Purity by HPLC: 99.91%, Particle size distribution: Dv(10): 7.409 μm, 
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